Clinical Trial

Discontinuation Study

Recruiting
View on ClinicalTrials.gov →
Summary
An interventional, non-randomised study to assess the risk of progression after discontinuation of maintenance therapy in sustained MRD negative complete remission by flow cytometry MM patients without high-risk features who have completed at least two years of maintenance therapy or who have discontinued maintenance due to side effects. The primary endpoint is to assess the rates of sustained MRD negativity by NGF in the bone marrow at 12 months after discontinuation of maintenance therapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-05-10; most recent amendment 2026-03-02.
Status change: Not Yet Recruiting → Recruiting 2023-11-07
Trial Details
NCT Number NCT05866757
Lead Sponsor University College Cork
Collaborators: Cancer Research@UCC
Conditions Multiple Myeloma, Cancer, Hematologic Cancer
Enrollment 70 participants
Start Date 2023-08-28
Primary Completion 2027-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-04